Viveve Medical (NASDAQ: VIVE) is one of 82 public companies in the “Advanced Medical Equipment & Technology” industry, but how does it compare to its rivals? We will compare Viveve Medical to similar companies based on the strength of its earnings, institutional ownership, risk, valuation, profitability, analyst recommendations and dividends.

Earnings & Valuation

This table compares Viveve Medical and its rivals top-line revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Viveve Medical $10.42 million -$25.39 million -2.59
Viveve Medical Competitors $2.02 billion $430.74 million -70.34

Viveve Medical’s rivals have higher revenue and earnings than Viveve Medical. Viveve Medical is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Risk and Volatility

Viveve Medical has a beta of -0.49, indicating that its stock price is 149% less volatile than the S&P 500. Comparatively, Viveve Medical’s rivals have a beta of 0.89, indicating that their average stock price is 11% less volatile than the S&P 500.

Institutional & Insider Ownership

65.6% of Viveve Medical shares are owned by institutional investors. Comparatively, 53.0% of shares of all “Advanced Medical Equipment & Technology” companies are owned by institutional investors. 35.1% of Viveve Medical shares are owned by company insiders. Comparatively, 17.2% of shares of all “Advanced Medical Equipment & Technology” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.


This table compares Viveve Medical and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Viveve Medical -266.93% -244.96% -97.99%
Viveve Medical Competitors -327.91% -35.29% -12.43%

Analyst Ratings

This is a breakdown of recent ratings for Viveve Medical and its rivals, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Viveve Medical 0 0 4 0 3.00
Viveve Medical Competitors 253 1813 3257 105 2.59

Viveve Medical presently has a consensus price target of $10.50, indicating a potential upside of 91.26%. As a group, “Advanced Medical Equipment & Technology” companies have a potential downside of 6.85%. Given Viveve Medical’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Viveve Medical is more favorable than its rivals.

Viveve Medical Company Profile

Viveve Medical, Inc. designs, develops, manufactures and markets a medical device, Geneveve, for the non-invasive treatment of vaginal laxity, for improved sexual function, and for vaginal rejuvenation. The Company’s, Geneveve, is a non-invasive solution for vaginal laxity, which includes three components: the Viveve System (a radio frequency (RF), generator housed in a table-top console), a reusable handpiece and a single-use treatment tip, as well as several other consumable accessories. Physicians attach the single-use treatment tip to the handpiece, which is connected to the console. The generator authenticates the treatment tip and programs the system for the desired treatment without further physician intervention. The treatment is performed in a physician’s office, in less than 30 minutes, and does not require the use of anesthesia. Geneveve is indicated for use in general surgical procedures for electrocoagulation and hemostasis in the United States.

Receive News & Ratings for Viveve Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical Inc. and related companies with's FREE daily email newsletter.